Menu Share Market Today LIVE | Sensex, Nifty, BSE, NSE, Share Prices, Stock Market News Updates June 22 – Tehuty Finance

Share Market Today LIVE | Sensex, Nifty, BSE, NSE, Share Prices, Stock Market News Updates June 22

0


Share Market Today, Share Market LiveExcept for Nifty IT, all the sectoral indices ended the session in green

Share Market News Today | Sensex, Nifty, Share Prices LIVE: Domestic equity market benchmarks BSE Sensex and Nifty 50 settled over half a per cent higher in Monday’s session led by buying in metals, banks and pharma stocks. The 30-share Sensex advanced 180 points or 0.52 per cent to end the session at 34,911, while the broader Nifty 50 index settled at 10,311, up 67 points or 0.65 per cent. Out of 30 Sensex stocks, 21 scrips finished trade in the positive territory. Bajaj-Auto was top Sensex gainer with a growth of 7 per cent, followed by Bajaj Finance, Bajaj Finserv, Kotak Mahindra Bank, Power Grid Corporation of India and NTPC. On the other hand, HDFC was the top laggard on the Sensex pack. ONGC, TCS, Reliance Industries (RIL), HDFC Bank, Infosys and M&M were among top losers. Except for Nifty IT, all the sectoral indices ended the session in green. Nifty Metal gained 2.62 per cent and Nifty Pharma jumped 2.16 per cent in today’s trade. Only the Nifty IT index declined and closed 0.25 per cent lower.

Drug firm Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate Covid-19 at a price of about Rs 103 per tablet. “It offers a rapid reduction in viral load within 4 days and provides faster symptomatic and radiological improvement. Of most importance, Favipiravir has shown clinical improvement of up to 88 per cent in Covid-19 mild to moderate COVID-19 cases including those with co-morbidities,” the statement said.

Read More


Leave A Reply

Your email address will not be published.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More